/Investor DB

Healthequity — 2018 Investments

1 investments dated 2018 · listed companies and verified rows first · show all

Minoryx Therapeuticsminoryx.cominSep 2018 · $24.8M

Minoryx is a registration-stage biotech company developing novel therapies for severe, orphan genetic diseases of the central nervous system, with a lead compound (leriglitazone) in clinical trials for conditions including cerebral adrenoleukodystrophy, Friedreich's Ataxia, and Rett syndrome.

BiotechDeep TechHealthtechMedical DevicesMataró, ES

Marc Martinell(Co-Founder & Chief Executive Officer)in

Co-investorsChiesi VenturesCriteria Bio VenturesFund+Invivo Capital PartnersKurma PartnersRoche Venture Fund+5 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.